MedPath

Fasudil

Generic Name
Fasudil
Drug Type
Small Molecule
Chemical Formula
C14H17N3O2S
CAS Number
103745-39-7
Unique Ingredient Identifier
Q0CH43PGXS
Background

Fasudil has been investigated in Carotid Stenosis.

Indication

用于改善蛛网膜下隙出血后的脑血管痉挛及伴发的脑缺血症状。

Clinical Trials
Related News

A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer

Phase 2
Recruiting
Conditions
Ovarian Cancer
Interventions
First Posted Date
2025-03-24
Last Posted Date
2025-03-24
Lead Sponsor
Zhejiang Provincial People's Hospital
Target Recruit Count
20
Registration Number
NCT06890858
Locations
🇨🇳

Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)

Phase 2
Recruiting
Conditions
Alzheimer Disease
Cognitive Decline, Mild
Interventions
Drug: Placebo
First Posted Date
2024-04-12
Last Posted Date
2024-10-22
Lead Sponsor
Helse Stavanger HF
Target Recruit Count
200
Registration Number
NCT06362707
Locations
🇳🇴

University Hospital of North Norway, Tromsø, Nordland, Norway

🇳🇴

Haugesund Hospital, Haugesund, Rogaland, Norway

🇳🇴

Stavanger University Hospital, Stavanger, Rogaland, Norway

and more 3 locations

Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease

Phase 2
Recruiting
Conditions
Idiopathic Parkinson´s Disease
Interventions
Drug: Placebo
First Posted Date
2023-07-05
Last Posted Date
2023-09-26
Lead Sponsor
Technical University of Munich
Target Recruit Count
75
Registration Number
NCT05931575
Locations
🇩🇪

Technische Universität München, Klinikum rechts der Isar, Klinik und Poliklinik für Neurologie, Munich, Germany

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

Phase 2
Active, not recruiting
Conditions
Amyotrophic Lateral Sclerosis
Interventions
First Posted Date
2022-02-01
Last Posted Date
2025-04-08
Lead Sponsor
Woolsey Pharmaceuticals
Target Recruit Count
40
Registration Number
NCT05218668
Locations
🇺🇸

Neuromuscular Research Center, Phoenix, Arizona, United States

🇺🇸

University of Colorado, Aurora, Colorado, United States

🇺🇸

National Jewish Health, Denver, Colorado, United States

and more 9 locations

Fasudil fOr redUcing elopemeNt and Spatial Disorientation

Phase 2
Completed
Conditions
Dementia
Interventions
Drug: Oral Placebo
First Posted Date
2021-03-11
Last Posted Date
2022-07-11
Lead Sponsor
Woolsey Pharmaceuticals
Target Recruit Count
24
Registration Number
NCT04793659
Locations
🇺🇸

Albuquerque Neuroscience Inc., Albuquerque, New Mexico, United States

🇦🇺

Modbury Hospital, Modbury, South Australia, Australia

🇦🇺

Barwon Geriatrics, Geelong, Victoria, Australia

and more 8 locations

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

Phase 2
Conditions
Progressive Supranuclear Palsy
Corticobasal Syndrome
Interventions
First Posted Date
2021-02-02
Last Posted Date
2022-06-03
Lead Sponsor
Woolsey Pharmaceuticals
Target Recruit Count
15
Registration Number
NCT04734379
Locations
🇺🇸

University of California Weill Institute for Neurosciences, San Francisco, California, United States

Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)

Phase 2
Conditions
Retinopathy of Prematurity
Interventions
Drug: receive artificial tears drop
First Posted Date
2019-12-10
Last Posted Date
2019-12-10
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
184
Registration Number
NCT04191954
Locations
🇮🇷

Ophthalmic Research Center, Tehran, Iran, Islamic Republic of

Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Placebo
First Posted Date
2019-01-03
Last Posted Date
2023-11-30
Lead Sponsor
University Medical Center Goettingen
Target Recruit Count
120
Registration Number
NCT03792490
Locations
🇫🇷

Centre Hospitalier Universitaire Tours, Tours, France

🇩🇪

University Medical Center Göttingen, Göttingen, Germany

🇩🇪

Klinikum rechts der Isar der Technischen Universität München, München, Germany

and more 12 locations

Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction

Phase 4
Conditions
ST Segment Elevation Myocardial Infarction
Interventions
Drug: Placebo saline
First Posted Date
2018-11-26
Last Posted Date
2018-11-26
Lead Sponsor
RenJi Hospital
Target Recruit Count
600
Registration Number
NCT03753269

Red Blood Cell ATP Release and Vascular Function in Humans

Phase 2
Completed
Conditions
Cardiovascular Diseases
Interventions
Other: Saline
First Posted Date
2018-01-19
Last Posted Date
2020-02-27
Lead Sponsor
Colorado State University
Target Recruit Count
31
Registration Number
NCT03404843
Locations
🇺🇸

Colorado State University, Dept. of Health and Exercise Science, Fort Collins, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy